The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study was to see the effectiveness of azithromycin in preventing the incidence of
bronchopulmonary dysphasia in extremely preterm and very premature infants. Inclusion
criteria were infants with a gestational age of 25-31 weeks 6 days who experienced
respiratory distress and their families had agreed to participate in the study, then
randomized. The intervention was in the form of giving azithromycin in the intervention group
and no intervention was carried out in the control group and then followed up to 36 weeks PMA